62.4 F
New York
Monday, May 17, 2021

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Must read

Oaktree [NASDAQ: OCSL] Announces Pricing of Underwritten Public Offering

Oaktree Specialty Lending Corporation disclosed that it has set the price of an underwritten public offering of $350.0 million aggregate principal amount of...

Black.one Introduces Cryptocurrency Exchange Venture with $10B in Funding

Black.one has disclosed Tuesday that it has launched Bullish Global. Bullish Global is a subsidiary of Black.one. It is a new blockchain-based cryptocurrency exchange...

Pfizer-BioNTech COVID-19 Vaccine Gets FA Approval for Emergency Use in Adolescents

Pfizer Inc. and BioNTech SE disclosed that its COVID-19 vaccine has got the FDA approval for its COVID-19 vaccine. After the approval,...

Soliton [NASDAQ: SOLY] to be Acquired by Allergan Aesthetics

Soliton, Inc. disclosed Monday that it has inked an agreement with Allergen Aesthetics. As per the agreement, Allergen Aesthetics will buy Soliton. Allergen...

Clene Inc. [NASDAQ: CLNN] disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene Nanomedicine is the subsidiary of CNN. Additionally, the notices include device and process entitled for its platform technology and sophisticated stage clean-surfaced nanocrystal therapeutic candidates.

The first allowed application named “Continuous Methods for Treating Liquids and Manufacturing Certain Constituents in Liquids, Apparatuses, and Nanoparticles and Nanoparticle/Liquid Solution(s) Resulting Therefrom”. It includes a vast range of device privileges related to electrochemical technology platforms for CLNN for making solutions and suspensions.

Furthermore, it has been disclosed that both patents, once granted, will continue to offer important intellectual property protection for CNM-Au8. CNM-Au8 is the top drug candidate of Clene. CNM-Au8 is now being assessed across seven clinical studies for the cure of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease.

Additionally, the global patent portfolio in the new field of clean-surfaced nanocrystal therapeutics of Clene now covers over 130 patents. These patents are granted and allowed. Moreover, it has been disclosed that nearly 30 more applications are still waiting.

Additionally, the granted patents include state of matter claims for suspensions and solutions, as well as processes for making the materials, devices for overseeing the unique electro-crystal chemistry processes, and methods of using the novel materials.

More articles

Latest article

Elon Musk’s SpaceX to Roll Out Dogecoin-Backed Satellite to the Moon in 2022

Elon Musk’s SpaceX has decided to recognize Dogecoin as payment to roll out its “DOGE-1 Mission to the Moon”. The mission is going to...

SBI CEO Yoshitaka Kitao Reveals Ripple to Go Public after its Legal Battle with the SEC is Over

CEO of Japanese financial services company SBI Holdings, Yoshitaka Kitao disclosed that Ripple has opted for an option to go public once its legal...

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...